Europe’s economic slump has been a clear driver for the uptake of biosimilars as governments seek to slash their health budgets. But original product manufacturers may still be able to alter that trend by lowering their own prices before biosimilars uptake becomes routine.
Speaking at the European Generic medicines Association’s 12th International Biosimilars Conference on April 3, Alan Sheppard, Global Head Generics, Thought...